talazoparib plus enzalutamide for prostatic neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 29 Mar 2021: Trial registered, NCT04821622
  2. 12 May 2021: Trial started, NCT04821622

The trials

NCT04821622: Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

State
Under way
Phase
Phase 3
People
599 taking part
Started
12 May 2021
Primary completion
18 Feb 2026
Arms
Arm 1
Results
None posted
  1. 29 Mar 2021: Trial registered
  2. 12 May 2021: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.